Cue Biopharma (CUE) Retained Earnings (2017 - 2025)
Cue Biopharma (CUE) has disclosed Retained Earnings for 9 consecutive years, with -$368.5 million as the latest value for Q4 2025.
- Quarterly Retained Earnings fell 7.78% to -$368.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$368.5 million through Dec 2025, down 7.78% year-over-year, with the annual reading at -$368.5 million for FY2025, 7.78% down from the prior year.
- Retained Earnings hit -$368.5 million in Q4 2025 for Cue Biopharma, down from $1000.0 in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $1000.0 in Q3 2025 to a low of -$368.5 million in Q4 2025.
- Historically, Retained Earnings has averaged -$219.5 million across 5 years, with a median of -$276.8 million in 2023.
- Biggest five-year swings in Retained Earnings: tumbled 803841.03% in 2024 and later skyrocketed 100.0% in 2025.
- Year by year, Retained Earnings stood at -$189.1 million in 2021, then skyrocketed by 99.95% to -$96000.0 in 2022, then tumbled by 313639.58% to -$301.2 million in 2023, then decreased by 13.5% to -$341.9 million in 2024, then dropped by 7.78% to -$368.5 million in 2025.
- Business Quant data shows Retained Earnings for CUE at -$368.5 million in Q4 2025, $1000.0 in Q3 2025, and -$362.6 million in Q2 2025.